

Supporting Information for

Evolution of Angiotensin Peptides and Peptidomimetics as AT2 Receptor Agonists

Silvana Vasile¹, Anders Hallberg², Jessica Sallander¹, Mathias Hallberg³, Johan Åqvist¹ and Hugo Gutiérrez-de-Terán^{1*}

¹ Department of Cell and Molecular Biology, Uppsala University, Biomedical Centre (BMC), BOX 596, SE-751 24 Uppsala, and Sweden and Science for Life Laboratory, BMC (H.G.T.); silvana.vasile@icm.uu.se (S.V.); johan.aqvist@icm.uu.se (J.Å.)

² Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, BMC, Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden; anders.hallberg@ikl.uu.se

³ The Beijer Laboratory, Department of Pharmaceutical Biosciences, Division of Biological Research on Drug Dependence, BMC, Uppsala University, P.O. Box 591, SE-751 24 Uppsala, Sweden; Mathias.Hallberg@farmbio.uu.se

* Correspondence: hugo.gutierrez@icm.uu.se; Tel.: +46(0)18-471-5056

Table of contents

Figure S1	2
Figure S2	3
Figure S3	4
Figure S4	5
Figure S5	6
Figure S6	7
Figure S7	8
Figure S8	9
Figure S9	9
Figure S10.....	10
Figure S11.....	10
Figure S12.....	11
Figure S13.....	12
Table S1	13




Figure S1 Comparison of the relative position of His⁶ in AT1R (yellow) and AT2R (green)




Figure S2: Binding pocket of sarile (1) in AT2R




Figure S3: Binding mode of compound 2




Figure S4: Binding mode of compound 3




Figure S5: Binding mode of compound 4




Figure S6: Binding mode of compound 5




Figure S7: Binding mode of compound 6




Figure S8: Comparison of the C-terminus orientation of **4** with co-crystallised AT2 antagonist




Figure S9: Comparison of the binding modes of **6** and **11**. The NH₂ of **11** is an extension of the gamma-turn mimic of **6**




Figure S10: Comparison of the binding modes of sarile in AT1R (green) and AT2R (cyan).




Figure S11: Sarile (green) and AngII (brown) C-terminal residues, overlaid with our docked compounds (green=3, cyan=4, yellow=5, magenta=6). The predicted rotamer of the Phe is actually the same as in AngII




Figure S12: Comparison between the docking poses of compound 6 based on sarile or ATII-bound ATR structures. A) AT2R with sarile-based modelling in violet, AngII-based model in gray. B) AT1 structure, with sarile-based model in magenta, AngII-model in green.




Figure S13: Average RMSD of each system subjected to 3×10 ns of MD simulations. Black lines represent the average RMSD of the ligands, red lines represent the average RMSD of the binding sites and green lines represent the average RMSD of the complexes (receptor-ligand).

Table S1: Relative binding affinity (in terms of experimental and calculated shifts in the free energy of binding) between two pairs of AT2 agonists, assuming the same binding pocket for the Phe/Ile sidechain on the C-terminus (related to Table 1).

Mutation	Chemical modification	$\Delta\Delta G_{\text{exp}} \pm \text{s.e.m. (kcal/mol)}$	$\Delta\Delta G_{\text{calc}} \pm \text{s.e.m. (kcal/mol)}$
8 $\rightarrow$ 7_{alternative}	Ile $\rightarrow$ Phe	1.54 ± 0.06	-0.41 ± 0.58
10 $\rightarrow$ 9_{alternative}	Ile $\rightarrow$ Phe	2.38 ± 0.07	-0.96 ± 0.76